The Reforming Evergreening and Manipulation that Extends Drug Years Act (REMEDY Act) amends the Federal Food, Drug, and Cosmetic Act to alter how abbreviated new drug applications (ANDAs) are approved. It introduces a formal designation called the “covered patent” and requires the sponsor to select one patent when submitting information related to certification.
That selection is fixed and cannot be changed later. The bill also revises when patent-infringement actions may be brought, expanding the set of patents that can be targeted (either the patent subject to certification or the designated covered patent) and clarifying the relationship between patent challenges and the 30-month stay.
The overarching goal is to deter evergreening tactics that extend drug exclusivity by aligning litigation triggers with a defined patent subset and the timing of application substantial completeness.
At a Glance
What It Does
Adds a 'covered patent' concept and fixes a single patent to anchor litigation and regulatory delays; expands infringement triggers to include actions against the patent or the covered patent.
Who It Affects
ANDA filers, brand-name patent holders, generic manufacturers, and FDA enforcement staff who oversee patent certifications and enforceability windows.
Why It Matters
Sets clearer limits on how patent-based delays can arise in generic drug approvals, potentially accelerating competition and lowering costs for payers and patients.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The REMEDY Act tightens how patent protection interacts with the approval of generic drugs. When an applicant files for an ANDA, the bill requires the applicant to pick one patent to designate as the “covered patent.” That choice applies to the associated patent challenges and cannot be changed after submission, creating a fixed target for litigation and regulatory timing.
For infringement actions, the bill modifies who can be sued and when—allowing suits not only against the traditional patent but also against the designated covered patent, depending on whether the drug was approved before or after the enactment date. This structure also reshapes how the 30-month regulatory delay is applied, tying it to the covered patent in post-enactment approvals and ensuring timelines reflect the qualified patent.
The intent is to reduce opportunities to prolong drug exclusivity through overlapping or shifting patent claims, thereby enabling earlier entry of generics into the market while maintaining a framework for legitimate patent enforcement.
The Five Things You Need to Know
The bill creates a 'covered patent' and requires selecting one patent when certifying an ANDA.
Once selected, the 'covered patent' cannot be changed after submission.
Infringement actions can target either the patent or the covered patent described in the certification.
The 30-month stay framework is adjusted to relate to the covered patent for post-enactment approvals.
The application timing and 'substantial completeness' determinations affect when and how infringement actions may be brought.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Amendments to ANDA approval provisions
Section 2 adds the concept of a 'covered patent' to the certification process and requires the applicant to designate one patent as the covered patent for the purposes of eligibility for the thirty-month period and related remedies. The selection must be maintained once chosen, and the language sets the covered patent as the reference point in certain infringement scenarios, changing the traditional binary patent challenge dynamic.
Revised infringement triggers for post-enactment drugs
The text alters the timing and scope of infringement actions, allowing challenges to the patent or the covered patent that is the subject of the certification. It ties these actions to the date of enactment and to the information submitted under the certification, intending to curb post-approval patent manipulation that would extend exclusivity.
30-month stay mechanics tied to the covered patent
The bill modifies how the thirty-month stay applies by designating the covered patent as the reference in the stay calculation for post-enactment approvals, and it clarifies the conditions under which a patent-related action can proceed within that period.
Substantial completeness and enforcement timing
The amendments reference the date on which an application, excluding amendments or supplements, is submitted and the Secretary’s subsequent determination of substantial completeness. This creates a more explicit linkage between filing milestones and enforcement action timing for both pre- and post-enactment drugs.
Stability of the designation and enforcement framework
The provisions reinforce that the covered patent designation is fixed once the information under the certification is submitted, reducing strategic shuffles of patent claims to delay litigation or market entry. This stability is intended to minimize gaming of the regulatory process while preserving clear rights for patent holders to pursue legitimate claims.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Generic drug manufacturers seeking earlier market entry due to tightened patent strategies and clearer timelines for litigation.
- Payors and healthcare systems potentially benefiting from earlier competition and lower drug costs.
- FDA’s Center for Drug Evaluation and Research, which gains clearer enforcement pathways and clearer triggers for action.
- Patients who stand to gain from earlier access to more affordable generics.
- Public health policy advocates concerned with curbing anti-competitive delays in drug markets.
Who Bears the Cost
- Brand-name patentees and licensees who rely on collaboration across a patent portfolio to delay competition.
- Small biotech and mid-size pharmaceutical entities facing increased risk of patent challenges and litigation costs.
- FDA and related agencies may face higher enforcement workload to implement and monitor the new designation and timing rules.
- Industry groups that must adapt to new compliance requirements and filing strategies.
- Payors and health systems might incur transition costs as market dynamics shift with earlier generic entry.
Key Issues
The Core Tension
The central dilemma is whether fixing a single 'covered patent' for a drug’s certification achieves the right balance between preventing evergreening and preserving legitimate patent protections that reward genuine innovation, while also ensuring timely generic competition.
The REMEDY Act introduces a structural shift in how patent protection interacts with generics by anchoring potential challenges to a single 'covered patent' per drug and by expanding the actionable universe for infringement theories. While this could curb opportunistic evergreening, it also concentrates enforcement risk on a narrower patent target, which could incentivize complex patent thickets or strategic filings around the designated patent.
The interplay with the 30-month stay, the substantial completeness milestone, and the date of enactment creates a delicate balance: it tightens timing and reduces post-submission maneuvering, but it may also raise uncertainty for complex portfolios where multiple patents could influence a generic’s path to market. Regulators must provide clear guidance to avoid inconsistent application across drug categories and ensure due process for patent holders in both pre- and post-enactment contexts.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.